CraigAlanBunnellMDMPH, MBA

Oncology • Boston, MA

Breast Cancer

Chief Medical Officer, Dana-Farber Cancer Institute

Join to view full profile

Dr. Bunnell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bunnell's full profile

Already have an account?

Office
450 Brookline Avenue
Dana Farber Cancer Institute
Boston, MA 02215
Phone+1 617-632-5024

Fax+1 617-582-7328

Education & Training

Massachusetts Institute of TechnologyMBA, Business/Management, 2006 - 2008
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1996
Brigham and Women's HospitalResidency, Internal Medicine, 1990 - 1993
Brigham and Women's HospitalInternship, Internal Medicine, 1990 - 1991
Harvard School of Public HealthMPH, 1988 - 1990
Harvard Medical SchoolClass of 1989, MD

Certifications & Licensure

MA State Medical License 1992 - 2025
ME State Medical License 2022 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer Start of enrollment: 2004 Jan 01
Terminated
Phase 2
Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer Start of enrollment: 2005 Oct 01
Completed
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer Start of enrollment: 2002 Apr 01
Completed
Not Applicable
Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer Start of enrollment: 2002 Mar 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Design and Implementation of an Opt-Out, End-to-End, PreemptiveTesting Program for Patients Planned for a Systemic Fluoropyrimidine.
Joseph O Jacobson, Garrett Rompelman, Angela Chen, Samantha Morrison-Ma, Lindsay Murray
JCO Oncology Practice. 2024-08-01
1 citations
NeuroinvasiveInfection in Immunocompromised Hosts: Epidemiologic Investigation of 5 Patients With Acute Myeloid Leukemia.
Jessica S Little, Cassie Coughlin, Candace Hsieh, Meaghan Lanza, Wan Yi Huang
Open Forum Infectious Diseases. 2024-03-01
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for...
Dario Trapani, Qingchun Jin, Caroline C Block, Rachel A Freedman, Nancy U Lin
JCO Oncology Practice. 2023-08-01

Press Mentions

Dana-Farber Praises Governor Healey for Signing New Law That Makes Cancer Screening More EquitableNovember 18th, 2024
Dana-Farber, Brigham Split Creates New Opportunities for Cancer CareNovember 1st, 2024
Late Stage Cancer Rates Could Rise if ACA Ruling Stands, Experts WorryMarch 31st, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member